Research and development expense in fiscal Q3 2025 -- $4.5 million versus $4.9 million in fiscal Q3 2024. Net loss -- $5.9 ...

Inovio Pharmaceuticals (INO) reported a disappointing 3Q25 with a GAAP EPS loss of -$0.87, missing consensus by $0.45 and ...

November 3, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced ...

Phase 2a data support oral C5aR inhibitor INF904 as a potentially transformational and best-in-class immunomodulatory agent, indicating strong ...

For more than two decades, Bracco has made education a cornerstone of progress in radiology. In 2024 alone, Bracco's educational programs reached over 100,000 healthcare professionals worldwide, ...

Income from operations of JD Retail was RMB14.8 billion (US$2.1 billion) for the third quarter of 2025, compared to RMB11.6 billion for the third quarter of 2024. Operating margin of JD Retail for the ...

MoneyWeek's experts tell us what they would go for if they could pick only one stock, sector or market for the next quarter-century. Tips range from defence and agriculture to Vietnam and Jardine Math ...

A mother and her daughter with a rare disease in Guangzhou, South China's Guangdong Province, on January 31, 2024 Photo: VCG.

Q3 2025 Earnings Call Transcript October 28, 2025 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $11.83, expectations were $9.65. Operator: Welcome to the Regeneron ...

Allergan Aesthetics, an AbbVie company , today announced it will present data highlighting efficacy, safety and patient-reported outcomes across its portfolio during the 2025 American Society of ...